Midtreatment evaluation of lymphoma response to chemotherapy by volume perfusion computed tomography

J Comput Assist Tomogr. 2014 Jan-Feb;38(1):123-30. doi: 10.1097/RCT.0b013e3182a90ee7.

Abstract

Objective: The aim of this study was to search for chemotherapy-induced perfusion changes of diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma at midtreatment versus baseline volume perfusion computed tomography (VPCT).

Methods: Forty-five consecutive patients with untreated diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma received VPCT examinations of the tumor bulk at baseline and during chemotherapy (midtreatment). Blood flow (BF), blood volume (BV), and transit constant (K-trans) were determined. Treatment response was categorized according to the Cheson criteria into complete or partial remission and stable or relapsed/progressive disease.

Results: Midtreatment follow-up showed a reduction in BF, BV, and K-trans in all lymphoma subtypes compared with baseline. The reduction in BV was less pronounced in larger tumors. Notably, BF, BV, and K-trans decreased in the responders (complete remission/partial remission) when compared with the nonresponders (stable or relapsed/progressive disease). Less than 10% reduction in BF was shown to be the best VPCT criterion for the identification of nonresponse.

Conclusions: Chemotherapy-induced perfusion changes in responders are recognizable at midtreatment VPCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Flow Velocity
  • Blood Volume
  • Cone-Beam Computed Tomography / methods*
  • Contrast Media
  • Female
  • Humans
  • Iohexol / analogs & derivatives
  • Lymphoma / diagnostic imaging*
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Treatment Outcome

Substances

  • Contrast Media
  • Iohexol
  • iopromide